Molecular features of ascitic ovarian cancer cells detected by immunofluorescence assay using flow cytometry
- 作者: Bogush T.A.1, Kaliuzhny S.A.1, Dudko E.A.1, Kirsanov V.Y.1, Tjulandina A.S.1, Bogush E.A.1, Tjulandin S.A.1, Davydov M.M.1
-
隶属关系:
- Blokhin Russian Cancer Research Center
- 期: 卷 71, 编号 5-6 (2016)
- 页面: 307-311
- 栏目: Article
- URL: https://bakhtiniada.ru/0027-1314/article/view/163321
- DOI: https://doi.org/10.3103/S0027131416050035
- ID: 163321
如何引用文章
详细
Peritoneal dissemination and growth of tumor cells in the ascitic fluid in stages III and IV of recurrent ovarian cancer is difficult to treat; resistance to many anticancer drugs used in the treatment of solid ovarian cancer is observed at this stage. The author’s hypothesis that the differences in the molecular phenotype of tumor cells for various types of the disease could be an explanation for this. A comparative evaluation of the expression and coexpression of a number of molecular markers (immunofluorescence assay with flow cytometry) was performed using solid and ascitic ovarian cancer cells. In contrast to solid ovarian cancer, ascitic ovarian cancer cells present leukocyte common antigen CD45 and mesenchymal marker vimentin in addition to epithelial marker cytokeratin. In addition to the inhibition of anoikis (specific mechanism of epithelial cell death in a liquid medium in the absence of contact with the substrate), ascitic ovarian cancer cells are characterized by (1) emperipolesis (intracellular migration of leukocytes without damage to the tumor cell), and (2) phenotype of epithelial-mesenchymal transition. Thus, the data on clinically significant molecular differences between solid and recurrent ascitic ovarian cancer was first obtained, opening up opportunities for anticancer therapy, which previously was not used in the treatment of ovarian cancer.
作者简介
T. Bogush
Blokhin Russian Cancer Research Center
编辑信件的主要联系方式.
Email: labmedchem@mail.ru
俄罗斯联邦, Moscow
S. Kaliuzhny
Blokhin Russian Cancer Research Center
Email: labmedchem@mail.ru
俄罗斯联邦, Moscow
E. Dudko
Blokhin Russian Cancer Research Center
Email: labmedchem@mail.ru
俄罗斯联邦, Moscow
V. Kirsanov
Blokhin Russian Cancer Research Center
Email: labmedchem@mail.ru
俄罗斯联邦, Moscow
A. Tjulandina
Blokhin Russian Cancer Research Center
Email: labmedchem@mail.ru
俄罗斯联邦, Moscow
E. Bogush
Blokhin Russian Cancer Research Center
Email: labmedchem@mail.ru
俄罗斯联邦, Moscow
S. Tjulandin
Blokhin Russian Cancer Research Center
Email: labmedchem@mail.ru
俄罗斯联邦, Moscow
M. Davydov
Blokhin Russian Cancer Research Center
Email: labmedchem@mail.ru
俄罗斯联邦, Moscow
补充文件
